Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 140 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Combined oral contraceptive Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

Optimizing Ovulation Induction in the Poor Responder

NCT01200537
View directory record Official record
Conditions
IVF Poor Responders
Interventions
Estradiol, Oral Contraceptive Pills (OCP)
Drug
Lead sponsor
Duke University
Other
Eligibility
20 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

NCT04756037
View directory record Official record
Conditions
Contraception
Interventions
Relugolix Combination Therapy
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
109
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 8, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 8, 2026, 10:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Influences of Long-acting Reversible Contraceptives on Iron Status and Physiological Responses to Extreme Environments in Women

NCT06909695
View directory record Official record
Conditions
Contraception, Iron Deficiencies
Interventions
Blood volume and environmental testing
Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

NCT05505162
View directory record Official record
Conditions
Healthy Female Participants
Interventions
Zibotentan, EE/LNG
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 8, 2026, 10:45 AM EDT
Terminated Phase 4 Interventional

Epidural Fentanyl for 2nd Stage Labor Analgesia

NCT03120780
View directory record Official record
Conditions
Labor Pain
Interventions
Fentanyl 20 mcg, Fentanyl 100 mcg
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Combined Hormonal Contraceptives on UPA

NCT02577601
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Levonorgestrel (LNG)/Ethinyl estradiol birth control pill
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 8, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS

NCT00722800
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
drospirenone and ethinyl estradiol (YAZ), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

NCT06820307
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine, DRSP/EE, NGM/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

NCT03783897
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305, Oral Contraceptive
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Liver and Fat Regulation in Overweight Adolescent Girls

NCT02157974
View directory record Official record
Conditions
Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
Interventions
Byetta 5Mcg Pen Injection
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

NCT03262727
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study

NCT02817841
View directory record Official record
Conditions
Contraception
Interventions
15 mg E4/3 mg DRSP
Drug
Lead sponsor
Estetra
Industry
Eligibility
16 Years to 50 Years · Female only
Enrollment
2,148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Desogestrel-containing COCP Pharmacokinetic Validation Study

NCT05002738
View directory record Official record
Conditions
Contraception
Interventions
Desogestrel and Ethinyl Estradiol Tablets
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 4 Interventional

Nurse Family Partnership (NFP) Contraceptive Study

NCT00928538
View directory record Official record
Conditions
Pregnancy, Effective Contraceptive Use, Family Planning
Interventions
Enhanced NFP Care
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Olympia, Washington • Seattle, Washington • Vancouver, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

NCT02367833
View directory record Official record
Conditions
Bone; Disorder, Development and Growth
Interventions
Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

NCT02922127
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Combined Oral Contraceptive Pill
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study

NCT01428713
View directory record Official record
Conditions
Menorrhagia
Interventions
Oral tranexamic acid, Oral Contraceptive Pills
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

NCT06071442
View directory record Official record
Conditions
Healthy Participants
Interventions
Vemircopan, Rosuvastatin, Metformin, Levonorgestrel / Ethinyl Estradiol, Carbamazepine
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Ovulation Incidence in Oral Contraceptive Users

NCT03106454
View directory record Official record
Conditions
Contraception, Ovulation
Interventions
Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate, Norethindrone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 8, 2026, 10:45 AM EDT
Completed No phase listed Observational

A Study to Look at Antiepileptic Drug Levels While on Lamictal or Depakote With or Without an Oral Contraceptive

NCT00296413
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 8, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)

NCT07225660
View directory record Official record
Conditions
Fertility Preservation
Interventions
OCP pause
Other
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Orange, Connecticut • Rockville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 8, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

NCT02792517
View directory record Official record
Conditions
Headache, Migraine
Interventions
Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
4
States / cities
Anaheim, California • Cypress, California • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 8, 2026, 10:45 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation

NCT00999479
View directory record Official record
Conditions
Endometrioma
Interventions
Norethindrone acetate and ethinyl estradiol tablets, USP, ferrous fumarate (placebo) tablets
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 8, 2026, 10:45 AM EDT